Peter De Porre
Overview
Explore the profile of Peter De Porre including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
2692
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Small E, Chi K, Chowdhury S, Bevans K, Bhaumik A, Saad F, et al.
Eur Urol Oncol
. 2023 Dec;
7(4):844-852.
PMID: 38072759
Background: Adding apalutamide to androgen-deprivation therapy (ADT) resulted in a rapid (at 3- and 6-mo treatment) and deep prostate-specific antigen (PSA) decline (to ≤0.2 ng/ml or ≥90% from baseline), improved...
2.
Pollock Y, Smith M, Saad F, Chowdhury S, Oudard S, Hadaschik B, et al.
Prostate Cancer Prostatic Dis
. 2023 Aug;
26(4):813.
PMID: 37620428
No abstract available.
3.
Chi K, Fleshner N, Chiuri V, Van Bruwaene S, Hafron J, McNeel D, et al.
Oncologist
. 2023 Mar;
28(5):e309-e312.
PMID: 36994854
Niraparib (NIRA) is a highly selective inhibitor of poly (adenosine diphosphate-ribose) polymerase, PARP1 and PARP2, which play a role in DNA repair. The phase II QUEST study evaluated NIRA combinations...
4.
Pollock Y, Smith M, Saad F, Chowdhury S, Oudard S, Hadaschik B, et al.
Prostate Cancer Prostatic Dis
. 2022 Oct;
26(1):156-161.
PMID: 36209239
Background: The phase III SPARTAN study demonstrated that apalutamide significantly improves metastasis-free survival and overall survival vs. placebo in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). However, patients receiving apalutamide...
5.
Wilson B, Armstrong A, de Bono J, Sternberg C, Ryan C, Scher H, et al.
Eur J Cancer
. 2022 May;
170:296-304.
PMID: 35568679
Background: The associations of metformin and statins with overall survival (OS) and prostate specific antigen response rate (PSA-RR) in trials in metastatic castration-resistant prostate cancer remain unclear. Objective: To determine...
6.
Dosne A, Valade E, Goeyvaerts N, De Porre P, Avadhani A, OHagan A, et al.
Cancer Chemother Pharmacol
. 2022 Jan;
89(2):151-164.
PMID: 34977972
Background: Exposure-response analyses were conducted to explore the relationship between selected efficacy and safety endpoints and serum phosphate (PO4) concentrations, a potential biomarker of efficacy and safety, in locally advanced...
7.
Saad F, De Porre P, Brookman-May S, Li J, McCarthy S, Rathkopf D
Lancet Oncol
. 2022 Jan;
23(1):e5-e6.
PMID: 34973233
No abstract available.
8.
Dosne A, Valade E, Stuyckens K, De Porre P, Avadhani A, OHagan A, et al.
CPT Pharmacometrics Syst Pharmacol
. 2021 Nov;
11(5):569-580.
PMID: 34755484
A population pharmacokinetic (PK)-pharmacodynamic (PD) model was developed using data from 345 patients with cancer. The population PK-PD model evaluated the effect of erdafitinib total and free plasma concentrations on...
9.
Saad F, Efstathiou E, Attard G, Flaig T, Franke F, Goodman Jr O, et al.
Lancet Oncol
. 2021 Oct;
22(11):1541-1559.
PMID: 34600602
Background: The majority of patients with metastatic castration-resistant prostate cancer (mCRPC) will have disease progression of a uniformly fatal disease. mCRPC is driven by both activated androgen receptors and elevated...
10.
Oudard S, Hadaschik B, Saad F, Cella D, Basch E, Graff J, et al.
Eur Urol Focus
. 2021 Sep;
8(4):958-967.
PMID: 34479838
Background: In SPARTAN, apalutamide improved metastasis-free and overall survival for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) with a prostate-specific antigen doubling time of ≤10 mo. Objective: We evaluated health-related...